138 related articles for article (PubMed ID: 28677033)
1. Preparation and evaluation of self-microemulsions for improved bioavailability of ginsenoside-Rh1 and Rh2.
Yang F; Zhou J; Hu X; Yu SK; Liu C; Pan R; Chang Q; Liu X; Liao Y
Drug Deliv Transl Res; 2017 Oct; 7(5):731-737. PubMed ID: 28677033
[TBL] [Abstract][Full Text] [Related]
2. Cytochromes P450 Inhibitory Excipient-Based Self-Microemulsions for the Improved Bioavailability of Protopanaxatriol and Protopanaxadiol: Preparation and Evaluation.
Yang F; Zhou J; Liu C; Hu X; Pan R; Chang Q; Liu X; Liao Y
Planta Med; 2017 Mar; 83(5):453-460. PubMed ID: 27220080
[TBL] [Abstract][Full Text] [Related]
3. Improving oral bioavailability of resveratrol by a UDP-glucuronosyltransferase inhibitory excipient-based self-microemulsion.
Yang FF; Zhou J; Hu X; Cong ZQ; Liu CY; Pan RL; Chang Q; Liu XM; Liao YH
Eur J Pharm Sci; 2018 Mar; 114():303-309. PubMed ID: 29292019
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of oral bioavailability and immune response of Ginsenoside Rh2 by co-administration with piperine.
Jin ZH; Qiu W; Liu H; Jiang XH; Wang L
Chin J Nat Med; 2018 Feb; 16(2):143-149. PubMed ID: 29455730
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms.
Yang Z; Gao S; Wang J; Yin T; Teng Y; Wu B; You M; Jiang Z; Hu M
Drug Metab Dispos; 2011 Oct; 39(10):1866-72. PubMed ID: 21757611
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics.
Zhang J; Zhou F; Niu F; Lu M; Wu X; Sun J; Wang G
PLoS One; 2012; 7(4):e35768. PubMed ID: 22530069
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo.
Shi J; Cao B; Zha WB; Wu XL; Liu LS; Xiao WJ; Gu RR; Sun RB; Yu XY; Zheng T; Li MJ; Wang XW; Zhou J; Mao Y; Ge C; Ma T; Xia WJ; Aa JY; Wang GJ; Liu CX
Acta Pharmacol Sin; 2013 Oct; 34(10):1349-58. PubMed ID: 23892274
[TBL] [Abstract][Full Text] [Related]
8. Characterization of pharmacokinetic profiles and metabolic pathways of 20(S)-ginsenoside Rh1 in vivo and in vitro.
Lai L; Hao H; Liu Y; Zheng C; Wang Q; Wang G; Chen X
Planta Med; 2009 Jun; 75(8):797-802. PubMed ID: 19266426
[TBL] [Abstract][Full Text] [Related]
9. Oral Nanomedicine Based on Multicomponent Microemulsions for Drug-Resistant Breast Cancer Treatment.
Qu D; Wang L; Liu M; Shen S; Li T; Liu Y; Huang M; Liu C; Chen Y; Mo R
Biomacromolecules; 2017 Apr; 18(4):1268-1280. PubMed ID: 28350158
[TBL] [Abstract][Full Text] [Related]
10. Enhancing in vivo oral bioavailability of cajaninstilbene acid using UDP-glucuronosyl transferase inhibitory excipient containing self-microemulsion.
Yang FF; Ji CY; Cong ZQ; Ma SQ; Liu CY; Pan RL; Chang Q; Ji YB; Liao YH
Colloids Surf B Biointerfaces; 2020 Sep; 193():111069. PubMed ID: 32371286
[TBL] [Abstract][Full Text] [Related]
11. Preparation of Polyethylene Glycol-Ginsenoside Rh1 and Rh2 Conjugates and Their Efficacy against Lung Cancer and Inflammation.
Mathiyalagan R; Wang C; Kim YJ; Castro-Aceituno V; Ahn S; Subramaniyam S; Simu SY; Jiménez-Pérez ZE; Yang DC; Jung SK
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795352
[TBL] [Abstract][Full Text] [Related]
12. 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions.
Zhang J; Zhou F; Wu X; Gu Y; Ai H; Zheng Y; Li Y; Zhang X; Hao G; Sun J; Peng Y; Wang G
Drug Metab Dispos; 2010 Dec; 38(12):2179-87. PubMed ID: 20837659
[TBL] [Abstract][Full Text] [Related]
13. The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers - An in vitro and in vivo comparison.
Weinheimer M; Fricker G; Burhenne J; Mylius P; Schubert R
Eur J Pharm Sci; 2017 Oct; 108():13-22. PubMed ID: 27590127
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs.
Gu Y; Wang GJ; Sun JG; Jia YW; Wang W; Xu MJ; Lv T; Zheng YT; Sai Y
Food Chem Toxicol; 2009 Sep; 47(9):2257-68. PubMed ID: 19524010
[TBL] [Abstract][Full Text] [Related]
15. Ginsenosides 20(S)-protopanaxadiol and Rh2 reduce cell proliferation and increase sub-G1 cells in two cultured intestinal cell lines, Int-407 and Caco-2.
Popovich DG; Kitts DD
Can J Physiol Pharmacol; 2004 Mar; 82(3):183-90. PubMed ID: 15052284
[TBL] [Abstract][Full Text] [Related]
16. Intestinal absorption mechanisms of ginsenoside Rh2: stereoselectivity and involvement of ABC transporters.
Gu Y; Wang GJ; Wu XL; Zheng YT; Zhang JW; Ai H; Sun JG; Jia YW
Xenobiotica; 2010 Sep; 40(9):602-12. PubMed ID: 20608841
[TBL] [Abstract][Full Text] [Related]
17. Excipient-mediated alteration in drug bioavailability in the rat depends on the sex of the animal.
Mai Y; Afonso-Pereira F; Murdan S; Basit AW
Eur J Pharm Sci; 2017 Sep; 107():249-255. PubMed ID: 28709912
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tissue distribution of ginsenoside Rh2 and Rg3 epimers after oral administration of BST204, a purified ginseng dry extract, in rats.
Bae SH; Park JB; Zheng YF; Jang MJ; Kim SO; Kim JY; Yoo YH; Yoon KD; Oh E; Bae SK
Xenobiotica; 2014 Dec; 44(12):1099-107. PubMed ID: 24933530
[TBL] [Abstract][Full Text] [Related]
19. Esterification enhanced intestinal absorption of ginsenoside Rh2 in Caco-2 cells without impacts on its protective effects against H₂O₂-induced cell injury in human umbilical vein endothelial cells (HUVECs).
Zhang B; Ye H; Zhu XM; Hu JN; Li HY; Tsao R; Deng ZY; Zheng YN; Li W
J Agric Food Chem; 2014 Mar; 62(9):2096-103. PubMed ID: 24524563
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of ginsenoside Rh1 inhibits the development of atopic dermatitis-like skin lesions induced by oxazolone in hairless mice.
Zheng H; Jeong Y; Song J; Ji GE
Int Immunopharmacol; 2011 Apr; 11(4):511-8. PubMed ID: 21238621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
